Approved Study Database
Ref. No. | Scientific Title | Principal investigator |
---|---|---|
2013.047 | An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A | Dr. LI Chi Kong |
2011.607 | An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia B | Dr. Li Chi Kong |
2011.606 | An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A | Dr. Li Chi Kong |
2017.178 | A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naïve severe aplastic anemia or recurrent aplastic anemia |
Prof. LI Chi Kong 李志光教授 |
2016.643 | Genotyping variants determining mercaptopurine tolerance in Chinese children with Acute Lymphoblastic Leukaemia |
Prof. LI Chi Kong 李志光 |
2016.406 | Genomic study on inherited bone marrow failure syndromes in Hong Kong by next generation sequencing |
Prof. LI Chi Kong 李志光 |
2017.012 | Asian-wide, multicenter open-label, phase II non-randomised study involving children with Down syndrome under 21 year-old with newly diagnosed, treatment naïve acute lymphoblastic leukemia |
Prof. LI Chi Kong 李志光 |
2017.355 | miRNA as diagnostic biomarkers for early detection of brain damage in acute leukaemia |
Prof. LI Chi Kong 李志光 |
2015.023 | Acute Lymphoblastic Leukaemia, Chinese Children Cancer Leukaemia Group 2015 Study | Dr. LI Chi Kong |
2017.610 | To study the effect of Syk inhibition or deletion on terminal erythropoiesis of human thalassemic hematopoietic and stem progenitors |
Prof. LI Chi Kong 李志光教授 |
2017.607 | Chinese Children Cancer Group Relapsed ALL 2017 Study |
Prof. LI Chi Kong 李志光 |
2017.625 | International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones: EsPhALL2017/COGAALL1631 |
Prof. LI Chi Kong 李志光 |
2017.606 | A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab versus no Prophylaxis in Hemophilia A Patients |
Prof. LI Chi Kong 李志光 |
2017.241 | Non-interventional Study on the Safety and Efficacy of Micafungin for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania – ERADICATE Study |
Prof. LI Chi Kong 李志光 |
2017.568 | An Open-Label Study of Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma |
Prof. LI Chi Kong 李志光教授 |
2016.247 | Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years with severe hemophilia A (FVIII < 1%) |
Dr. LI Chi Kong 李志光 |
2017.131 | Asparaginase activity and inhibitor in Chinese patients |
Prof. LI Chi Kong 李志光教授 |
2015.286 | A Phase 3b Continuation study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients with Severe Hemophilia A |
Dr. LI Chi Kong 李志光 |
2014.364 | A Phase 3 prospective, uncontrolled, multicenter study evaluating pharmacokinetics, efficacy, safety, and immunogenicity of BAX 855 (PEGylated full-length Recombinant FVIII) in previously treated pediatric patients with severe hemophilia A | Dr. LI Chi Kong |
2017.440 | The prevalence and clinical outcome of Ph-like Acute Lymphoblastic Leukaemia in a retrospective cohort |
Prof. LI Chi Kong 李志光 |
2014.462 | Phase II Trial of the Addition of Gemcitabine to 131I-MIBG Therapy in Paediatric Patients with Relapsed or Progressive Neuroblastoma | Dr. LI Chi Kong |
2015.631 | Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A |
Dr. LI Chi Kong 李志光醫生 |
2019.107 | Prevalence of Iron deficiency and its impact on neurocognitive function in Hong Kong adolescent |
Prof. LI Chi Kong 李志光 |
2019.519 | A single arm, open-labelled Phase II clinical trial of anti-CD19 chimeric antigen receptor modified T-cell (CAR-T) for treatment of B-cell haematological malignancies |
Prof. LI Chi Kong 李志光教授 |
2018.099 | Lifestyle modification program for treatment of nonalcoholic fatty liver disease in childhood cancer survivors |
Prof. LI Chi Kong 李志光 |
2019.173 | Life Functioning and Quality of Life in Adult Survivors of Childhood Cancer |
Prof. LI Chi Kong 李志光 |
2019.091 | A retrospective study on compassionate use of Inotuzumab Ozogamicin in infants and younger children with relapsed or refractory acute lymphoblastic leukemia (ALL) |
Prof. LI Chi Kong 李志光 |
2020.445 | A Phase II CCCG-ALL Multi-center Trial of Dasatinib in Combination with Intensive Induction Therapy for Children with First Relapsed T-cell Acute Lymphoblastic Leukemia |
Prof. LI Chi Kong 李志光 |
2020.035 | Evaluation of health-related quality of life and social support among caregivers of paediatric palliative care: A longitudinal prospective study |
Prof. LI Chi Kong 李志光 |
2018.303 | Registration in Center for International Blood and Marrow Transplant Research |
Prof. LI Chi Kong 李志光 |
2020.540 | Chinese Children’s Cancer Group Acute Lymphoblastic Leukemia-2020 Project (CCCG-ALL-2020) |
Prof. LI Chi Kong 李志光 |
2020.404 | Driving Therapeutic Progress of Childhood Leukemia through Advanced Translational Research with Immediate and Long-term Impact |
Prof. LI Chi Kong 李志光教授 |
2019.023 | Neuroimaging, Cognitive and Life Functioning Outcomes in Patients with Hemophilia |
Prof. LI Chi Kong 李志光 |
2019.704 | An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis |
Prof. LI Chi Kong 李志光教授 |
2019.297 | Retrospective review of bone health in transfusion dependent thalassemia patients in Hong Kong |
Prof. LI Chi Kong 李志光教授 |
2019.712 | The Prognostic factors of paediatric osteosarcoma in Hong Kong |
Prof. LI Chi Kong 李志光 |
2021.110 | Effect of cancer treatment on testicular function and semen quality in male childhood and adolescent cancer survivors |
Prof LI Chi Kong 李志光 |
2021.280 | Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia |
Prof. LI Chi Kong 李志光 |
2021.314 | Effect of cancer treatment in adolescents and early adults on uterus and endometrial function |
Prof Li Chi Kong 李志光 |
2013.394 | Development and Testing of a Self-management Model for Patients with Chronic Obstructive Pulmonary Disease | Miss LI CHING CHING |
2022.441 | Impact of pre-operative penicillin allergy evaluation on surgical prophylaxis: a randomized controlled trial | Dr. LI Chun Man |
2022.680 | A retrospective study on clinical characteristics and treatment outcomes in patients with acquired haemophilia A (AHA) in Hong Kong | Dr. LI Chung Hin |
2021.325 | Repetitive Negative Thinking of Patients with Common Mental Disorders: The Role of Goal Discrepancy, Rationality, and Psychological Flexibility |
Ms. LI Connie Suk Man 李淑雯 |
2011.509 | In vivo assessment of periaricular and generalized bone loss in patients with rheumatoid arthritis by high resolution peripheral quantitative computed tomography | Prof. LI Edmund |
2011.228 | Effects of inflammation on bone loss in rheumatoid arthritis: Does inflammation affect joints and bone equally? | Professor LI Edmund K |
2010.455 | A prospective case-control cost of illness studies in systemic lupus erythematosus | Prof. LI Edmund K |
2011.570 | Bone quality in men with rheumatoid arthritis: A case-control study using the high-resolution peripheral quantitative computed tomography | Prof. Li Edmund K |
2007.083 | Genetic Studies of Autoimmune Disease in Chinese | Prof. LI Edmund Kwok Ming |
2010.298 | A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid arthritis drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis | Professor Li Edmund Kwok Ming |
2010.463 | In vivo assessment of bone microarchitecture and bone perfusion in osteoporotic patients with systemic lupus erythematosus | Prof. Li Edmund Kwok-ming |
Page 145 of 254.